Physician profile
Dmitriy Romanenko
NPI 1881894715
$421.29
in general payments reported to CMS, 2019-2025
13 companies · $32.78 in 2025
The $32.78 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.50 · 2020: $115 · 2021: $77.69 · 2022: $31.88 · 2023: $42.86 · 2024: $70.31 · 2025: $32.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $189.16 | 2019-2021 | |
| Smith+Nephew, INC. | $41.96 | 2022-2023 | Pico |
| Merck Sharp & Dohme LLC | $38.82 | 2023-2024 | Capvaxive, Rotateq, Vaxneuvance |
| Regeneron Healthcare Solutions, INC. | $32.78 | 2025 | Dupixent |
| Hologic Sales and Service, LLC | $30.88 | 2024 | Aptima, Thinprep 2000 Processor |
| Allergan, INC. | $27.89 | 2019-2022 | |
| Genentech USA, INC. | $26.07 | 2021 | |
| Becton, Dickinson and Company | $19.64 | 2024 | Bd Onclarity |
| Roche Diagnostics Corporation | $14.09 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Romanenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.